GS
IONS icon

GTS Securities’s Ionis Pharmaceuticals IONS Stock Holding History

GTS Securities’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,000
Closed -$481K – 2613
2024
Q3 		$481K Sell
12,000
-49,400
-80% -$2.3M ﹤0.01% 2860
2024
Q2 		$2.93M Buy
61,400
+49,200
+403% +$2.02M 0.01% 1220
2024
Q1 		$529K Sell
12,200
-1,000
-8% -$47.7K ﹤0.01% 2532
2023
Q4 		$668K Sell
13,200
-11,100
-46% -$532K ﹤0.01% 2541
2023
Q3 		$1.1M Buy
+24,300
New +$1M ﹤0.01% 1936

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

GTS Securities's IONS Position: Q4 2024 in Review

GTS Securities sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 5,056 shares — an estimated $203K sold.

GTS Securities first reported a position in IONS in Q2 2024 and held it in 2 quarters. The position peaked at $2.9M in Q2 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • GTS Securities reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 5,056 Ionis Pharmaceuticals shares in Q4 2024, an estimated $203K.
  • GTS Securities first reported a position in Ionis Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • GTS Securities's Ionis Pharmaceuticals position peaked at $2.9M in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.